11 Oct 2019 07:01
Polarean Imaging Plc
("Polarean" or the "Company")
Polarean notes statement from Amphion Innovations
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, notes the announcement made today by its partner company, Amphion Innovations Plc ("Amphion") that the remainder of its 15,972,523 shares in Polarean have now been sold. As previously announced, Amphion's holding in Polarean shares was pledged as security against a loan facility and the shares were sold pursuant to this security arrangement.
Following this sale, Amphion no longer holds any shares in Polarean.
The full TR-1 disclosure is set out below.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i | ||||||
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: | Polarean Imaging plc | |||||
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) | ||||||
Non-UK issuer | ||||||
2. Reason for the notification (please mark the appropriate box or boxes with an "X") | ||||||
An acquisition or disposal of voting rights | X | |||||
An acquisition or disposal of financial instruments | ||||||
An event changing the breakdown of voting rights | ||||||
Other (please specify)iii: | ||||||
3. Details of person subject to the notification obligationiv | ||||||
Name | Amphion Innovations plc | |||||
City and country of registered office (if applicable) | ||||||
4. Full name of shareholder(s) (if different from 3.)v | ||||||
Name | ||||||
City and country of registered office (if applicable) | ||||||
5. Date on which the threshold was crossed or reachedvi: | October 8 2019 | |||||
6. Date on which issuer notified (DD/MM/YYYY): | October 10 2019 | |||||
7. Total positions of person(s) subject to the notification obligation | ||||||
% of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments(total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights of issuervii | |||
Resulting situation on the date on which threshold was crossed or reached | 0% | 114,438,600 | ||||
Position of previous notification (if applicable) | 13.96% | |||||
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii | |||||||||
A: Voting rights attached to shares | |||||||||
Class/type ofshares ISIN code (if possible) | Number of voting rightsix | % of voting rights | |||||||
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | ||||||
GB008BVVT4H71 | 0 | 0% | |||||||
SUBTOTAL 8. A | 0 | 0% | |||||||
| |||||||||
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | |||||||||
Type of financial instrument | Expirationdatex | Exercise/Conversion Periodxi | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | |||||
SUBTOTAL 8. B 1 | |||||||||
| |||||||||
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | |||||||||
Type of financial instrument | Expirationdatex | Exercise/Conversion Period xi | Physical or cash settlementxii | Number of voting rights | % of voting rights | ||||
SUBTOTAL 8.B.2 | |||||||||
| |||||||||
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") | ||||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii | X | |||
Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) | ||||
Namexv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
10. In case of proxy voting, please identify: | ||||
Name of the proxy holder | ||||
The number and % of voting rights held | ||||
The date until which the voting rights will be held | ||||
11. Additional informationxvi | ||||
Place of completion | London, UK |
Date of completion | October 8 2019 |
Enquiries:
Polarean Imaging plc | www.polarean.com / www.polarean-ir.com | |||
Richard Hullihen, Chief Executive Officer | Via Walbrook PR | |||
Richard Morgan, Chairman |
| |||
|
| |||
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 | |||
David Hignell / Soltan Tagiev (Corporate Finance) |
| |||
Vadim Alexandre / Rob Rees (Corporate Broking) |
| |||
| ||||
Walbrook PR | Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com | |||
Anna Dunphy / Paul McManus | Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 | |||